Efficacy of artemisinin-based combination therapy (ACT) in people living with HIV (PLHIV) diagnosed with uncomplicated Plasmodium falciparum malaria in Africa: a WWARN systematic review

Table 3 Estimated PCR-corrected risk of recrudescence in PLHIV co-infected with malaria

Study ID	Day	Malaria drug	HIV drug	PLHIV group		%	95%CI	HIV-uninfected comparator		%	95%CI
Study ID	Day	Malaria drug	HIV drug	N	n	%	95%CI	N	n	%	95%CI
3	28	ASAQ	TS + ART	35	0	0.0	0–10.0	258		3.6^a	1.9–6.9^a
11	28	AL	NVP	61	3	4.9	1.0–13.7	181	5	2.8	1.2–6.3
	28	AL	EFV	50	1	2.0	0.1–10.6	181	5	2.8	1.2–6.3
	28	AL	LPV/r	70	2	2.9	0.3–9.9	181	5	2.8	1.2–6.3
12	45	AL or SP	None	266	37	13.9	10.0–18.7	530	61	11.5	8.9–14.5
17	42	AL	EFV	134^b	0	0.0	0.0–2.8
18	42	DP	EFV	158^c	0	0.0	0.0–2.4
	42	DP	NVP	61	0	0.0	0.0–6.9

N = number of patients enrolled, and n = number of failures. If only n/N were provided in the publication, proportion and 95% CI for proportion were calculated (Wilson method) assuming no losses to follow-up
AL artemether-lumefantrine, ART antiretroviral therapy, ASAQ artesunate-amodiaquine, DP dihydroartemisinin-piperaquine, EFV efavirenz, LPV/r lopinavir/ritonavir, NVP nevirapine, SP sulfadoxine-pyrimethamine, TS trimethoprim-sulfamethoxazole prophylactic treatment
^aKM estimates are provided as reported in the publication
^bExcludes 10 lost to follow-up and 8 with PCR results indeterminate or unavailable
^cExcludes one early treatment failure and one with PCR result not available

ISSN: 1475-2875